SEC Form 4 · accession 0001209191-17-002630
FATE THERAPEUTICS INC · FATE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel D Shoemaker
Officer — Chief Scientific Officer
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434316
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $2.73 | Jan 4, 2017 | A | 150,000 | A | — | Jan 3, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021.
- F2Not applicable.